DE4334936C1 - Medicament for treating hypertension - Google Patents

Medicament for treating hypertension

Info

Publication number
DE4334936C1
DE4334936C1 DE19934334936 DE4334936A DE4334936C1 DE 4334936 C1 DE4334936 C1 DE 4334936C1 DE 19934334936 DE19934334936 DE 19934334936 DE 4334936 A DE4334936 A DE 4334936A DE 4334936 C1 DE4334936 C1 DE 4334936C1
Authority
DE
Germany
Prior art keywords
lithium
medicament
blood pressure
angiotensin
aspartate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19934334936
Other languages
German (de)
Inventor
Karla Dr Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19934334936 priority Critical patent/DE4334936C1/en
Priority to AU79377/94A priority patent/AU7937794A/en
Priority to EP94930168A priority patent/EP0723451B1/en
Priority to AT94930168T priority patent/ATE183645T1/en
Priority to DE59408666T priority patent/DE59408666D1/en
Priority to PCT/EP1994/003380 priority patent/WO1995010289A1/en
Application granted granted Critical
Publication of DE4334936C1 publication Critical patent/DE4334936C1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Medicament for treating hypertension and preventing its sequelae contains an ACE inhibitor (I) and a Li salt (II). (I) is pref. alacepril, benazepril, captopril, cilazapril, delapril, enalapril, fentiapril, fosinopril, lisinoprol, moveltipril, pentopril, perindopril, pivalopril, ramipril, quinapril, spirapril or zofenopril. (II) is Li acetate, adipate, aspartate, benzoate, bromide, chloride, fluconate, orotate, salicylate or citrate.

Description

Die Erfindung betrifft ein Arzneimittel zur optimierten Behandlung eines erhöhten Blutdrucks und zur Verhütung von Folgeerkrankungen.The invention relates to a medicament for the optimized treatment of an elevated Blood pressure and for the prevention of secondary diseases.

Bluthochdruck ist eine Volkskrankheit, die bekanntermaßen zusammen mit ihren Folgekrankheiten an der Spitze der Todesursachen steht. Bei 80-95% aller Hochdruckkrankheiten kann keine definitive Ursache gefunden werden; man nimmt eine multifaktorielle Genese an. Bekannt ist die Abhängigkeit der Blutdruckhöhe von der sympathischen (adrenergen) Aktivität, der Aktivität des Renin-Angiotensin-Aldosteron- Systems (RAAS) und der Höhe der Serum-Natriumkonzentrationen (Ganten/Ritz, 1985).Hypertension is a common disease that is known to coexist with theirs Consequential diseases are at the top of the causes of death. In 80-95% of all No definite cause can be found for high-pressure diseases; you take one multifactorial genesis. The dependence of the blood pressure level on the is known sympathetic (adrenergic) activity, the activity of renin-angiotensin-aldosterone Systems (RAAS) and the level of serum sodium concentrations (Ganten / Ritz, 1985).

Jeder chronisch erhöhte Blutdruck muß behandelt werden. Eine medikamentöse Monotherapie erzielt in der Regel jedoch nur bei zirka 50% der behandlungsbedürftigen Hochdruckkranken eine ausreichende Blutdrucksenkung. Auch ACE-Hemmer zeigen in Monotherapie kein besseres Ansprechen (Breithaupt, 1986). Ihr Wirkungsmechanismus beruht auf der Hemmung der Umwandlung von Angiotensin I in das pressorisch (blutdrucksteigernd) wirksame Angiotensin II. Dadurch sinkt auch die Aktivität von Aldosteron und die damit in Verbindung stehende Natrium-Reabsorption in der Niere, was zu einem Natrium-Verlust führt. Der Salzhunger wird bei sinkenden zentralen Angiotensin II- Wirkungen eingeschränkt. Die sich daraus summierende Hyponatriämie begünstigt die blutdrucksenkenden Eigenschaften der ACE-Hemmer in der Peripherie. Die Beziehung zwischen ansteigender Dosis und blutdrucksenkender Wirkung ist bei ACE-Hemmern schwach ausgeprägt; die optimale Wirkung stellt sich langsam innerhalb von ca. 3-4 Wochen ein.Any chronically elevated blood pressure must be treated. A drug However, monotherapy is usually only achieved in around 50% of those in need of treatment High-pressure sufferers a sufficient reduction in blood pressure. ACE inhibitors also show in Monotherapy did not respond better (Breithaupt, 1986). Your mechanism of action is based on the inhibition of the conversion of angiotensin I into the pressor (Blood pressure increasing) effective angiotensin II. This also reduces the activity of Aldosterone and the related sodium reabsorption in the kidney, leading to leads to sodium loss. Salt hunger is reduced when central angiotensin II Limited effects. The resulting hyponatremia favors the hypotensive properties of ACE inhibitors in the periphery. The relationship between increasing dose and hypotensive effect is with ACE inhibitors weakly pronounced; the optimal effect slowly arises within about 3-4 weeks a.

Vor diesem Hintergrund hatte sich die Erfinderin die Aufgabe gestellt, ein Arzneimittel zu schaffen, welches den Effekt der ACE-Hemmer auf den erhöhten Blutdruck und dessen Sekundärfolgen in optimaler Weise ergänzt und verbessert.Against this background, the inventor had set herself the task of administering a drug create what the effect of ACE inhibitors on the increased blood pressure and its Secondary consequences optimally supplemented and improved.

Diese Aufgabe wurde durch das erfindungsgemäße Arzneimittel zur optimierten Behandlung eines erhöhten Blutdrucks und zur Verhütung von Folgeerkrankungen gelöst, welches dadurch gekennzeichnet ist, daß es aus einer Kombination von Lithiumsalzen mit ACE- Hemmern sowie gegebenenfalls üblichen pharmazeutischen Trägern, Verdünnungsmitteln und/oder Hilfsstoffen besteht.This object was achieved by the medicament according to the invention for optimized treatment increased blood pressure and to prevent complications, which characterized in that it consists of a combination of lithium salts with ACE  Inhibitors and, if appropriate, customary pharmaceutical carriers, diluents and / or auxiliary substances.

Die Addition eines zweiten Arzneimittels mit blutdrucksenkender Wirkung verbessert in der Regel den Effekt und erhöht die Ansprechquote. Wegen der signifikanten Abhängigkeit der ACE-Hemmer-Wirkung vom Natriumhaushalt (niedriges Serum-Natrium erhöht den Effekt) und der damit in Zusammenhang stehenden Aktivierung des für den Blutdruck äußerst wichtigen Renin-Angiotensin-Aldosteron-Systems RAAS (niedriges Serum-Natrium aktiviert dieses System) sind alle pathophysiologischen Veränderungen und/oder die Gabe zusätzlicher Arzneimittel mit Auswirkung auf den Natriumhaushalt und/oder die Aktivität des RAAS von besonderer Bedeutung für die Wirksamkeit und Verträglichkeit von ACE-Hemmern.The addition of a second drug with an antihypertensive effect improves in the Control the effect and increase the response rate. Because of the significant dependence of the ACE inhibitor effect of sodium balance (low serum sodium increases the effect) and the related activation of the extreme for blood pressure important renin-angiotensin-aldosterone system RAAS (low serum sodium activated this system) are all pathophysiological changes and / or the administration of additional ones Medicinal products that affect sodium balance and / or RAAS activity of particular importance for the effectiveness and tolerance of ACE inhibitors.

Dies ist die Grundlage für die erfindungsgemäße Kombination mit Lithium. Durch Lithium werden alle oben angeführten Ursachen des erhöhten Blutdrucks bekämpft. Die synergistischen Wirkungen von Lithium beruhen auf seinen umfassenden Wirkungen, insbesondere auf der Senkung adrenerger (sympathischer) Funktionen und auf der Beeinflussung des RAAS sowie des Natriumhaushalts:This is the basis for the combination with lithium according to the invention. With lithium all of the above causes of increased blood pressure are addressed. The synergistic effects of lithium are based on its comprehensive effects, especially on lowering adrenergic (sympathetic) functions and on the Influencing the RAAS and the sodium balance:

  • 1. Lithium löst eine Abnahme der Angiotensin-(Reduktion auf ca. 1/5) und Noradrenalin- Pressor-Response (Reduktion auf ca. 1/2) nach Applikation ansteigender Dosen bei der Ratte aus (Heizmann, 1967).1. Lithium triggers a decrease in angiotensin (reduction to approx. 1/5) and noradrenaline Pressor response (reduction to approx. 1/2) after application of increasing doses the rat (Heizmann, 1967).
  • - Lithium führt in therapeutisch wirksamen Dosen (25-50 mmol/Tag) zur Abnahme der pressorischen Ansprechbarkeit auf Angiotensin beim Menschen (Erhöhung der Angiotensin-Dosen von 12,2 auf 17 ng/kg/min; Fleischer, 1971).- Lithium leads to a decrease in therapeutically effective doses (25-50 mmol / day) pressor responsiveness to angiotensin in humans (increase in Doses of angiotensin from 12.2 to 17 ng / kg / min; Fleischer, 1971).
  • - Lithium erhöht in therapeutisch wirksamen Dosen (32 mmol) die zu einer Blutdruck­ steigerung notwendigen Noradrenalin-Dosen (5,74 µg auf 7,49 µg) beim Menschen (Fann, 1972).- Lithium in therapeutically effective doses (32 mmol) increases blood pressure increase in necessary norepinephrine doses (5.74 µg to 7.49 µg) in humans (Fann, 1972).
  • - Lithium hemmt im Gegensatz zu zweiwertigen Ionen wie Mangan, Magnesium oder Kalzium die hochaffine Bindung von Angiotensin II an peripheren Gefäßrezeptoren (Catt, 1984) und wirkt damit synergistisch zu ACE-Hemmern.- Lithium inhibits in contrast to divalent ions such as manganese, magnesium or Calcium the high affinity binding of angiotensin II to peripheral vascular receptors (Catt, 1984) and thus acts synergistically with ACE inhibitors.
  • - Intrazellulär hemmt Lithium einerseits die für die Vermittlung adrenerger sympathischer Effekte wichtige Adenylatzyklase. Andererseits senkt Lithium über eine nicht­ kompetitive Hemmung der Monophosphatase den Abbau von Inositphosphaten zu Inosit (Griendling, 1987; Nahorski 1991). Längerfristig resultiert aus dieser Lithiumwirkung eine Depletion von IP₃, dem wichtigsten Vermittler der intrazellulären Angiotensin II-Wirkungen.- On the one hand, intracellularly inhibits lithium, which is more sympathetic to the mediation of adrenergic Effects of important adenylate cyclase. On the other hand, lithium does not lower over one competitive inhibition of monophosphatase to break down inositol phosphates Inositol (Griendling, 1987; Nahorski 1991). In the longer term this results Lithium action a depletion of IP₃, the main mediator of intracellular angiotensin II effects.
  • 2. Lithium löst eine nachweisbare Natriurese aus und kann Natrium (blutdrucksteigernd) im Organismus ersetzen.2. Lithium triggers a detectable natriuresis and can sodium (increasing blood pressure) in the Replace organism.

Unterstützt werden diese Effekte durch eine lithiumbedingte Hemmung der vasopressinabhängigen Wasserreabsorption im distalen Tubulus der Niere, woraus eine zusätzliche Kreislaufentlastung resultiert.These effects are supported by a lithium-related inhibition of the vasopressin-dependent water absorption in the distal tubule of the kidney, resulting in a additional circuit relief results.

Insgesamt erweist sich demzufolge Lithium als idealer und physiologischer Wirkpartner von ACE-Hemmern.Overall, lithium proves to be the ideal and physiological active partner of ACE inhibitors.

Durch die erfindungsgemäße fixe Kombination eines ACE-Hemmers mit einem Lithiumsalz werden alle bekannten Ursachen des erhöhten Blutdrucks bekämpft bei gleichzeitiger verbesserter und verbreiterter Wirksamkeit der ACE-Hemmer. Bei Kombination beider Arzneimittel kann die übliche Dosierung der Komponenten gesenkt werden, wodurch die Verträglichkeit des ACE-Hemmers verbessert wird.By the fixed combination of an ACE inhibitor according to the invention with a lithium salt all known causes of increased blood pressure are combated while at the same time improved and broadened effectiveness of ACE inhibitors. When combining both Drugs can lower the usual dosage of the components, reducing the Tolerability of the ACE inhibitor is improved.

In zweckmäßiger Weise übersteigt in den erfindungsgemäßen Arzneimitteln die Dosierung der Komponenten die heute üblichen Tagesdosen nicht. Das Wirkverhältnis der Lithiumsalze zu den ACE-Hemmern ist so abzustimmen, daß daraus eine Erhöhung der blutdrucksenken­ den Wirksamkeit resultiert. Die synergistische blutdrucksenkende Wirksamkeit der Lithiumsalze wird auf den molaren Lithium-Gehalt des entsprechenden Salzes bezogen. Die erfindungsgemäßen Arzneimittel werden bevorzugt oral oder intravenös verabreicht.The dosage in the medicaments according to the invention expediently exceeds of the components not the usual daily doses today. The effect ratio of the lithium salts The ACE inhibitors should be coordinated so that they result in an increase in blood pressure drops the effectiveness results. The synergistic antihypertensive effectiveness of Lithium salts are based on the molar lithium content of the corresponding salt. The Medicaments according to the invention are preferably administered orally or intravenously.

Die erfindungsgemäßen Arzneimittel lassen sich in üblicher pharmazeutischer Weise zu den gewünschten Darreichungsformen konfektionieren, wobei Trägerstoffe, Verdünnungsmittel und/oder Hilfsstoffe eingesetzt werden können.The medicaments according to the invention can be added to the in the usual pharmaceutical manner pack the desired dosage forms, using carriers, diluents and / or auxiliaries can be used.

Quellensources

Breithaupt, H.: Behandlung der Hypertonie
Schattauer Verlag, Stuttgart-New York (1986)
Catt, K.J., Mendelsohn, FAC., Millan, M.A., Aguilera, G.: The role of angiotensin II receptors in vascular regulation
J. Cardiovasc. Pharmacol. 6 Suppl. 4; 8575-8586 (1984)
Fann, W.E., Davis, J.M., Janowski, D.S., Cavanaugh, J.H., Kaufmann, J.S., Griffith, J.D., Oates, J.A.:
Effects of Lithium on adrenergic function in man
Clin. Pharmacol. Ther. 13/1: 71-77 (1972)
Fleischer, K., Biniek, E., Klaus, D., Tölle, R.: Beeinflussung des Plasmarenins und der pressorischen Ansprechbarkeit auf Angiotensinamid durch Lithium beim Menschen
Arzneim.-Forsch. 21/9: 1363-1464 (1971)
Ganten, D. und Ritz, E. (ed.): Lehrbuch der Hypertonie
Schattauer Verlag, Stuttgart-New York (1985)
Griendling, K.K., Berk, C.B., Ganz, P., Gimbrone, M.A., Alexander, R.W.:
Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism
Hypertension 9 Suppl. III: III181-III185 (1987)
Heizmann, A., Klaus, D.: Der Einfluß von Lithiumchlorid auf die Blutdruckwirkung von Renin, Angiotensin und Noradrenalin bei Ratten
Klin. Wschr. 45/13: 659-660 (1967)
Nahorski, St. R., Ragan, C.I., Challiss, R.A.J.: Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences Trends in Pharmacol. Sci. 12/8: 297-303 (1991).Breithaupt, H .: Treatment of hypertension
Schattauer Verlag, Stuttgart-New York (1986)
Catt, KJ, Mendelsohn, FAC., Millan, MA, Aguilera, G .: The role of angiotensin II receptors in vascular regulation
J. Cardiovasc. Pharmacol. 6 Suppl. 4; 8575-8586 (1984)
Fann, WE, Davis, JM, Janowski, DS, Cavanaugh, JH, Kaufmann, JS, Griffith, JD, Oates, JA:
Effects of Lithium on adrenergic function in man
Clin. Pharmacol. Ther. 13/1: 71-77 (1972)
Fleischer, K., Biniek, E., Klaus, D., Tölle, R .: Influence of plasma arenin and the pressor responsiveness to angiotensinamide by lithium in humans
Pharmaceutical research 21/9: 1363-1464 (1971)
Ganten, D. and Ritz, E. (ed.): Textbook of hypertension
Schattauer Verlag, Stuttgart-New York (1985)
Griendling, KK, Berk, CB, Ganz, P., Gimbrone, MA, Alexander, RW:
Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism
Hypertension 9 Suppl. III: III181-III185 (1987)
Heizmann, A., Klaus, D .: The influence of lithium chloride on the blood pressure effects of renin, angiotensin and noradrenaline in rats
Klin. Wschr. 45/13: 659-660 (1967)
Nahorski, St. R., Ragan, CI, Challiss, RAJ: Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences Trends in Pharmacol. Sci. 12/8: 297-303 (1991).

Claims (3)

1. Arzneimittel zur optimierten Behandlung eines erhöhten Blutdruckes und der Verhütung von Folgeerkrankungen, enthaltend einen ACE-Hemmer in üblichen pharmazeutischen Trägern, Verdünnungsmitteln und/oder Hilfsstoffen, dadurch gekenn­ zeichnet, daß außerdem Lithiumsalze enthalten sind.1. Medicament for the optimized treatment of elevated blood pressure and the prevention of secondary diseases, containing an ACE inhibitor in conventional pharmaceutical carriers, diluents and / or auxiliaries, characterized in that lithium salts are also present. 2. Arzneimittel nach Anspruch 1, dadurch gekennzeichnet, daß die genannten Lithiumsalze aus Lithiumazetat, -adipinat, -aspartat, -hydrogenaspartat, -benzoat, -bromid, -chlorid, -glukonat, -orotat, -salizylat und/oder -zitrat bestehen.2. Medicament according to claim 1, characterized in that the said lithium salts from lithium acetate, adipinate, -aspartate, -hydrogen aspartate, -benzoate, -bromide, -chloride, gluconate, orotate, salicylate and / or citrate. 3. Arzneimittel nach Anspruch 1, dadurch gekennzeichnet, daß die genannten ACE-Hemmer aus Alacepril, Benazepril, Captopril, Cilazapril, Delapril, Enalapril, Fentiapril, Fosinopril, Lisinopril, Moveltipril, Pentopril, Perindopril, Pivalopril, Ramipril, Quinapril, Spirapril, Zofenopril sowie deren wirksame Metaboliten bestehen.3. Medicament according to claim 1, characterized in that the ACE inhibitors from alacepril, benazepril, Captopril, cilazapril, delapril, enalapril, fentiapril, Fosinopril, Lisinopril, Moveltipril, Pentopril, Perindopril, Pivalopril, Ramipril, Quinapril, Spirapril, Zofenopril and their effective metabolites exist.
DE19934334936 1993-10-13 1993-10-13 Medicament for treating hypertension Expired - Fee Related DE4334936C1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE19934334936 DE4334936C1 (en) 1993-10-13 1993-10-13 Medicament for treating hypertension
AU79377/94A AU7937794A (en) 1993-10-13 1994-10-13 Use of lithium compounds for treating high blood pressure
EP94930168A EP0723451B1 (en) 1993-10-13 1994-10-13 Use of lithium compounds in combination with ace-inhibitors and/or angiotensin ii -receptor antagonist for treating high blood pressure
AT94930168T ATE183645T1 (en) 1993-10-13 1994-10-13 USE OF LITHIUM COMPOUNDS IN COMBINATION WITH ACE INHIBITORS AND/OR ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ELEVATED BLOOD PRESSURE
DE59408666T DE59408666D1 (en) 1993-10-13 1994-10-13 USE OF LITHIUM COMPOUNDS IN COMBINATION WITH ACE INHIBITORS AND / OR ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR TREATING INCREASED BLOOD PRESSURE
PCT/EP1994/003380 WO1995010289A1 (en) 1993-10-13 1994-10-13 Use of lithium compounds for treating high blood pressure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19934334936 DE4334936C1 (en) 1993-10-13 1993-10-13 Medicament for treating hypertension

Publications (1)

Publication Number Publication Date
DE4334936C1 true DE4334936C1 (en) 1995-06-22

Family

ID=6500079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19934334936 Expired - Fee Related DE4334936C1 (en) 1993-10-13 1993-10-13 Medicament for treating hypertension

Country Status (1)

Country Link
DE (1) DE4334936C1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127469A1 (en) * 1991-08-20 1993-02-25 Peter Prof Dr Med Eckert Compsn. contg. chemotherapeutic agent and lithium salt - for treatment of bacterial or viral infection e.g. HSV and HIV, malaria, leishmaniasis, trypanosoma infection and Candida albicans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127469A1 (en) * 1991-08-20 1993-02-25 Peter Prof Dr Med Eckert Compsn. contg. chemotherapeutic agent and lithium salt - for treatment of bacterial or viral infection e.g. HSV and HIV, malaria, leishmaniasis, trypanosoma infection and Candida albicans

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BREITHAUPT, H.: Behandlung der Hypertonie, Schattauer Verlag, Stuttgart-New York(1986) *
CATT, K.J., MENDELSOHN, F.A.C., MILLAN, M.A, Aguilera, G.: The role of angiotensin II receptors in vascular regulation, J. Cardiovasc. Pharmacol. 6 Suppl. 4, S. 575-S.586(19894) *
C-J.(Hrsg.) Lehrbuch der allgemeinen und systematischen Pharmalogie und Toxikologie, Schattauer, Stuttgart, 1986, S. 166-167, 312-315 *
DE-B.: ESTLER *
FANN, W.E., DAVIS, J.M., JANOWSKI, D.S., CAVANAUGH, J.H., KAUFMANN, J.S., GRIFFITH, J.D., OATES, J.A.: Effects of Lithium on adrenergic function in man Clin. Pharmacol. Ther. 13/I:71-77,(1972) *
FLEISCHER, K., BINIEK, E., KLAUS, D., TÖLLE, R.: Beeinflussung des Plasmarenins und der pressorischen Ansprechbarkeit auf Angiotensinamid durch Lithium beim Menschen, Arzneim.-Forsch. 21/9:1363-1464(1971) *

Similar Documents

Publication Publication Date Title
Luke Mechanism of cyclosporine-induced hypertension
Todd et al. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure
DE69912434T2 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL DYSPEPSY AND / OR THE IRRIDAL SYNDROME AND THE USE OF NEW SUBSTANCES IN THIS COMPOSITION
Neutel et al. Combination therapy with diuretics: an evolution of understanding
Tytgat Colloidal bismuth subcitrate in peptic ulcer-a review
SK11522000A3 (en) A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
Desai Hyperkalemia in patients with heart failure: incidence, prevalence, and management
JPS62103027A (en) Ace inhibitor for ophthalmic spot degeneration
US4983598A (en) Pharmaceutical composition containing diltiazem and angiotensin-converting enzyme inhibitor
Waeber et al. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity
HU224009B1 (en) Phartmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
Shionoiri et al. Fosinopril: clinical pharmacokinetics and clinical potential
EP1014989B1 (en) Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
DE4334936C1 (en) Medicament for treating hypertension
Kato et al. Role of peripheral capsaicin-sensitive neurons and CGRP in central vagally mediated gastroprotective effect of TRH
DE4339848C2 (en) Medicines to optimize the treatment of high blood pressure and to prevent secondary diseases
KR19990023021A (en) New medicinal uses
Ribeiro et al. The renin-angiotensin system in the control of systemic arterial pressure
Chrysant et al. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients
Cheung Blockade of the renin-angiotensin system
Ando et al. The role of renal hemodynamics in the antihypertensive effect of captopril
Bivins et al. Clinical failures with cimetidine
DE4334927C1 (en) Use of lithium salts
EP0723451B1 (en) Use of lithium compounds in combination with ace-inhibitors and/or angiotensin ii -receptor antagonist for treating high blood pressure
EP0730471B1 (en) Use of lithium compounds in the treatment of cardiac insufficiency

Legal Events

Date Code Title Description
8100 Publication of the examined application without publication of unexamined application
D1 Grant (no unexamined application published) patent law 81
8322 Nonbinding interest in granting licenses declared
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee